The Cigna Group
CI
$270.73
-0.73%
The Cigna Group is a diversified healthcare services company operating primarily in the Medical - Healthcare Plans industry, providing pharmacy benefit management (PBM) and health insurance services. It is a major integrated player, distinct for its massive PBM and specialty pharmacy platform, Evernorth, which was significantly expanded through the 2018 merger with Express Scripts, and its employer-focused health insurance business. The current investor narrative is dominated by the company's strategic review of its eviCore medical benefits management unit and its exit from the individual public exchange market, moves aimed at streamlining operations and focusing on core, profitable growth segments, as evidenced by its recent strong quarterly results and raised guidance, which are being weighed against the potential execution risks of this strategic pivot.…
CI
The Cigna Group
$270.73
Related headlines
Investment Opinion: Should I buy CI Today?
Rating & Thesis: Hold. Cigna presents a compelling value proposition with strong cash flows and a cheap valuation, but these are currently offset by significant technical weakness, margin pressure, and execution risks, warranting a neutral stance until the price trend confirms a reversal. This aligns with the analyst consensus which is bullish on fundamentals but must contend with the stock's persistent underperformance.
Supporting Evidence: The primary valuation metric, a forward P/E of 8.28x, represents a steep discount and implies significant earnings growth from the estimated $45.81 EPS. Revenue growth remains positive at 10.39% YoY in Q4, though it is moderating. Profitability is solid with an ROE of 14.28%, but the recent sequential margin decline is a concern. The company's massive $8.39B TTM free cash flow generation is a key strength, supporting shareholder returns.
Risks & Conditions: The two biggest risks are the continuation of the technical downtrend and further margin compression. This Hold rating would upgrade to a Buy if the stock decisively breaks above the $300 resistance level on sustained volume, signaling an end to the downtrend, or if quarterly gross margins stabilize above 8%. It would downgrade to a Sell if the price breaks below the $239.51 support or if revenue growth decelerates below 5% YoY. The stock is undervalued relative to its earnings power but fairly valued given the current growth and sentiment headwinds.
Sign up to view all
CI 12-Month Price Forecast
Cigna is a classic case of strong fundamentals trapped in a weak technical pattern. The valuation is undeniably cheap, and the cash flow story is robust, supported by unanimous analyst bullishness. However, the stock's persistent underperformance, low beta, and recent margin pressure create a significant headwind. The investment thesis hinges on whether the strategic pivot can catalyze a sentiment shift. The stance is neutral with medium confidence, as the base case of range-bound trading seems most probable. An upgrade to bullish would require a confirmed technical breakout above $300 coupled with margin stabilization. A downgrade to bearish would be triggered by a break below the $239.51 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $351.95 and implied upside of +30.0% versus the current price.
Average Target
$351.95
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$217 - $352
Analyst target range
Analyst coverage for Cigna is robust, with 5 major firms providing estimates, and the institutional sentiment is overwhelmingly positive, as recent actions from firms like Bernstein (upgraded to Outperform), Piper Sandler, Truist, Barclays, and Guggenheim are all Buy or Overweight ratings. The consensus recommendation is bullish, with an average EPS estimate of $45.81 for the coming period, implying strong earnings growth from the Q4 2025 EPS of $4.64. The average revenue estimate is $338.1 billion, suggesting continued top-line expansion.
The target price range, while not explicitly provided in the data points, can be inferred from the high level of institutional bullishness and the implied growth in EPS estimates, which range from $44.40 to $47.24. The tight range of these EPS estimates (a spread of only about 6.4%) indicates strong analyst conviction in the company's near-term earnings trajectory. The recent news of raised guidance and strategic reviews likely supports the high-end targets, which would factor in successful execution of the strategic pivot and sustained margin performance. The low-end estimates likely incorporate risks related to the strategic review execution, potential regulatory headwinds for PBMs, and integration challenges. The uniform bullish stance among covering analysts, with no Sell ratings in the recent data, signals strong institutional support for the stock at current levels.
Bulls vs Bears: CI Investment Factors
The evidence presents a clear tension between strong fundamental value and persistent negative price momentum. The bull case is anchored in deep valuation discounts, robust cash flow, solid profitability, and unanimous analyst support following a strategic pivot. The bear case is driven by a clear technical downtrend, recent margin compression, low growth expectations, and execution risks. Currently, the bear side has stronger short-term evidence, as price action and momentum are decisively negative, overshadowing the attractive fundamentals. The single most important tension is whether the company's strategic focus and raised guidance can overcome the entrenched negative market sentiment and break the stock's technical downtrend, thereby allowing the fundamental value to be recognized.
Bullish
- Deeply Discounted Forward Valuation: Cigna trades at a forward P/E of just 8.28x based on estimated EPS of $45.81, a significant discount to its trailing P/E of 12.29x. This implies the market is pricing in strong earnings growth, which is supported by the company's recent guidance raise and robust analyst consensus.
- Strong Cash Flow Generation: The company generates substantial free cash flow, with TTM FCF of $8.39 billion. This provides ample internal funding for its 2.2% dividend yield (payout ratio 27%), share repurchases, and strategic investments, underpinning shareholder returns.
- Solid Profitability and Returns: Cigna maintains solid profitability metrics, including a Q4 2025 net margin of 1.70% and a full-year Return on Equity of 14.28%. These figures demonstrate efficient capital allocation and the ability to generate returns in a competitive industry.
- Unanimous Analyst Bullishness: Recent analyst actions from five major firms, including upgrades to Outperform and Buy ratings, reflect strong institutional conviction. The tight EPS estimate range ($44.40 to $47.24) indicates confidence in the near-term earnings trajectory.
Bearish
- Persistent Technical Downtrend: The stock is in a sustained downtrend, with a 1-year price change of -11.10% and a 3-month change of -4.29%, significantly underperforming the S&P 500. It trades near the 38.2% level of its 52-week range ($239.51 to $338.89), closer to its lows.
- Recent Margin Compression: Q4 2025 gross margin declined sequentially to 7.66% from 8.52% in Q3, and operating margin fell to 2.96% from 3.70%. This pressure, likely from the mix of lower-margin PBM revenue, threatens profitability if it persists.
- Low Growth and Market Volatility: With a beta of 0.31, the stock exhibits roughly 70% less volatility than the market, often a sign of a defensive laggard. Its 6-month price change of only +0.04% and sequential revenue growth of 3.9% (Q3 to Q4) suggest a mature, low-growth profile.
- Execution Risk in Strategic Pivot: The strategic review of eviCore and exit from the individual exchange market introduce near-term execution and integration risks. Any misstep could disrupt operations and undermine the rationale for the streamlined focus, as highlighted in recent news.
CI Technical Analysis
The stock is in a sustained downtrend, evidenced by a 1-year price change of -11.10% and a 6-month change of only +0.04%, underperforming the S&P 500 significantly over both periods. Currently trading at $277.40, the price sits at the 38.2% level of its 52-week range ($239.51 to $338.89), indicating it is much closer to its yearly lows than highs and suggesting the stock is in a value zone but still facing significant downward pressure. The 1-month price change of -5.10% and 3-month change of -4.29% confirm the bearish momentum has persisted in the near term, with the stock's recent weakness diverging sharply from the S&P 500's positive performance over the same periods, as shown by the -11.41 and -14.57 relative strength figures. This consistent underperformance, coupled with a beta of 0.313 indicating the stock is far less volatile than the market, suggests it is being treated as a defensive laggard rather than a growth vehicle, with momentum firmly to the downside.
Key technical support is clearly defined at the 52-week low of $239.51, while major resistance sits at the 52-week high of $338.89. A decisive break below the $239.51 support would signal a continuation of the downtrend and potentially open the door to further significant losses, while a recovery above the $300 level would be needed to challenge the primary downtrend. The stock's exceptionally low beta of 0.31, indicating it is roughly 70% less volatile than the broader market, is a double-edged sword: it may limit downside volatility in a market sell-off but also suggests muted participation in any market rally, requiring investors to size positions accordingly for its unique risk-return profile.
The price action over the last six months shows a volatile but ultimately directionless consolidation, with the stock failing to sustain a breakout above $300 in late April 2026 before retreating back to the $277-$290 range. The recent 1-month decline of -5.10% occurred on elevated average daily volume of approximately 2.4 million shares, suggesting the selling pressure is being met with conviction. The stock's maximum drawdown of -28.12% over the period underscores the significant capital erosion experienced by holders, reinforcing the prevailing bearish trend that has been in place for the past year.
Beta
0.31
0.31x market volatility
Max Drawdown
-28.1%
Largest decline past year
52-Week Range
$240-$339
Price range past year
Annual Return
-13.1%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | +5.0% |
| 3m | -3.7% | +10.7% |
| 6m | +2.0% | +10.0% |
| 1y | -13.1% | +26.5% |
| ytd | -3.0% | +10.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory shows steady growth, with Q4 2025 revenue reaching $72.47 billion, representing a 10.39% year-over-year increase. Segment data reveals this growth is heavily driven by the massive Evernorth PBM segment, which contributed $64.74 billion in the latest period, dwarfing the $12.51 billion from the Cigna Healthcare insurance segment. However, sequential quarterly revenue from Q3 to Q4 2025 grew only 3.9% ($69.75B to $72.47B), suggesting a potential moderation in the growth rate as the company cycles past strong post-pandemic periods. The top-line expansion is robust but appears to be normalizing from the high single-digit to low double-digit pace seen in prior quarters.
The company remains solidly profitable, posting Q4 2025 net income of $1.23 billion and a net margin of 1.70%. Gross margin for the quarter was 7.66%, a sequential decline from the 8.52% in Q3 2025, indicating some margin pressure, likely from the mix of lower-margin PBM revenue. Operating margin for the quarter was 2.96%, down from 3.70% in the prior quarter, reflecting the gross margin compression and ongoing investments. Despite the quarterly dip, the full-year profitability metrics, like a Return on Equity (ROE) of 14.28%, demonstrate the company's ability to generate solid returns on shareholder capital in a competitive, regulated industry.
Cigna's balance sheet is healthy, with a manageable debt-to-equity ratio of 0.75 and a current ratio of 0.85, indicating sufficient liquidity for its operational model. The company is a strong cash flow generator, with trailing twelve-month free cash flow of $8.39 billion, providing ample internal funding for growth initiatives, dividends (with a payout ratio of 27.04%), and share repurchases. The ROA of 4.78% and ROE of 14.28% indicate efficient use of assets and equity, though the sub-1.0 current ratio is typical for managed care companies that operate with significant medical claims payables.
Quarterly Revenue
$72.5B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.07%
Latest Quarter
Free Cash Flow
$8.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Given Cigna's positive and substantial net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 12.29x and a forward PE of 8.28x based on estimated EPS of $45.81. The significant discount of the forward PE relative to the trailing figure implies the market anticipates strong earnings growth in the coming year, aligning with the company's recent guidance raise.
Compared to typical healthcare plan and PBM peers, Cigna's trailing PE of 12.3x appears to be at a discount, though a precise industry average is not provided in the data. The forward PE of 8.3x suggests an even steeper discount is priced in. This valuation discount may be attributed to investor concerns over regulatory scrutiny of PBMs, the strategic uncertainty highlighted by the eviCore review, and the company's lower growth profile compared to pure-play technology or biotech names in the healthcare sector. The valuation seems to price in these overhangs rather than the company's stable cash flow generation.
Historically, Cigna's trailing PE has fluctuated significantly, from a high of 32.63x in Q3 2024 to a low of 10.27x in Q3 2025, with the current 12.29x sitting near the midpoint of this recent range. The Price-to-Sales ratio of 0.27 is near the lower end of its historical spectrum observed in the data (e.g., 1.01 in Q4 2025, 1.31 in Q2 2025). This positioning suggests the stock is not at extreme historical valuation levels but is valued conservatively, possibly reflecting a market view that it is a mature, cash-generative business with limited secular growth catalysts.
PE
12.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -94x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cigna faces margin pressure, with Q4 gross margin compressing 86 bps sequentially to 7.66% and operating margin falling 74 bps to 2.96%. While the balance sheet is healthy (Debt/Equity 0.75), the sub-1.0 current ratio (0.85) is typical for managed care but indicates reliance on managing medical claims payables. Revenue concentration is a risk, with the Evernorth PBM segment contributing $64.74B of the Q4 $72.47B total, creating dependency on the sustainability of PBM economics amid regulatory scrutiny.
Market & Competitive Risks: The stock's low beta (0.31) suggests it is treated as a defensive laggard, limiting upside participation in market rallies as evidenced by its -39.31 relative strength vs. the S&P 500 over one year. The forward P/E of 8.3x, while cheap, may reflect a permanent discount due to sector overhangs like PBM regulation and perceived low growth, risking valuation compression if these concerns intensify. Competitive pressures in both PBM and insurance markets could further squeeze margins and market share.
Worst-Case Scenario: A failure in the strategic pivot, combined with intensified PBM regulation and a broader market downturn, could trigger a re-test of the 52-week low of $239.51. Given the stock's maximum drawdown of -28.12% over the past year, a similar adverse scenario from the current price of $277.40 implies a realistic downside of approximately -14% to that key support level. A break below $239.51 could signal a continuation of the downtrend, potentially leading to further losses beyond the historical low.
FAQ
The key risks are, in order of severity: 1) Technical & Sentiment Risk: The stock is in a clear downtrend, underperforming the S&P 500 by 39 percentage points over one year, indicating persistent selling pressure. 2) Margin Risk: Sequential gross margin compression (8.52% to 7.66%) threatens profitability if it becomes a trend. 3) Execution Risk: The strategic pivot, including the eviCore review and exit from individual exchanges, introduces operational uncertainty. 4) Regulatory Risk: The core PBM business faces ongoing political and regulatory scrutiny that could impact its lucrative model.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $285 and $310, driven by steady execution and meeting its $45.81 EPS estimate. The Bull Case (30% probability) targets $315 to $340, requiring a successful strategic pivot and a break of the downtrend. The Bear Case (20% probability) risks a fall to $240-$270, re-testing the 52-week low on execution missteps or worsened margins. The Base Case is most likely, implying modest upside from current levels, but the wide range reflects the high uncertainty between fundamental value and technical momentum.
CI stock is fundamentally undervalued based on earnings. Its forward P/E ratio of 8.28x represents a significant discount to its own trailing P/E of 12.29x and is low compared to typical healthcare plan peers, though a precise industry average is not provided. The Price-to-Sales ratio of 0.27 is also near the low end of its historical range. This valuation implies the market expects limited growth and is pricing in overhangs like PBM regulatory risk. Therefore, it is undervalued on an absolute earnings basis but may be fairly valued relative to its current growth profile and sector sentiment.
CI is a good buy for value and income-focused investors who can tolerate near-term volatility and are investing with a multi-year horizon. The forward P/E of 8.3x is deeply discounted, and the 2.2% dividend is supported by $8.39B in annual free cash flow. However, it is not a good buy for momentum traders or those seeking high growth, given its persistent technical downtrend (-11.1% over one year) and low beta. The biggest risk is further price erosion if the downtrend continues. It is best bought in phases on further weakness, targeting the lower end of its 52-week range.
CI is far more suitable for a long-term investment horizon of 3-5 years. Its low beta (0.31) and defensive business model provide stability, while its high cash flow generation and dividend are benefits that compound over time. The current valuation discount may take several quarters or years to close, requiring patience. It is poorly suited for short-term trading due to its weak momentum, low volatility, and lack of near-term catalysts. A minimum holding period of 18-24 months is suggested to allow the fundamental story and capital return program to potentially outweigh the technical headwinds.